Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Related SNY
Medivation's Take-Out Price Raised To $68-$78 At Citi
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid
Disney V DreamWorks Showdown (Seeking Alpha)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News


Related Articles (SNY)

View Comments and Join the Discussion!